top of page

Psychedelics and Mental Health: Current Research and Applications

Psychedelics are a class of drugs known for their ability to induce profound changes in consciousness. Over the past decade, there has been a resurgence of interest in their therapeutic potential for mental health conditions. This shift is largely due to a new wave of rigorous, controlled clinical research exploring the benefits and risks of these substances. This blog post delves into the current research on psychedelics and their potential applications in mental health treatment.

Psychedelics and Mental Health: A Historical Perspective

Psychedelic substances, such as psilocybin (found in "magic mushrooms") and lysergic acid diethylamide (LSD), were subjects of extensive research in psychiatry during the mid-20th century. However, due to political and social backlash, this research was abruptly halted, leaving many potential applications unexplored. Fast forward to the 21st century, the scientific community is resuming its investigation into these substances with renewed vigor and optimism. Today, clinical trials on psychedelics' therapeutic applications are conducted under rigorous ethical and safety guidelines, with early results promising potential breakthroughs in mental health treatment.

Current Research on Psychedelics

Recent research has revealed several promising areas where psychedelics may contribute to mental health treatment:

  1. Treatment-Resistant Depression: Multiple studies have shown that psilocybin, coupled with psychological support, can lead to significant and sustained reductions in depression symptoms. A small trial conducted by Imperial College London reported that all participants experienced a decrease in depression symptoms one week after treatment, with about two-thirds maintaining this improvement five weeks later.

  2. Anxiety and End-of-Life Distress: In studies with patients experiencing life-threatening cancer diagnoses, both psilocybin and LSD have shown promise in alleviating anxiety and depression associated with facing mortality.

  3. Post-Traumatic Stress Disorder (PTSD): MDMA (commonly known as "Ecstasy") has been used in conjunction with psychotherapy to treat PTSD. A study published in Nature Medicine in 2021 found that MDMA-assisted therapy was significantly more effective than psychotherapy alone in reducing PTSD symptoms.

  4. Addiction: Preliminary studies suggest that psilocybin therapy may be effective in treating substance use disorders, including alcohol and tobacco addiction.

Psychedelics and Therapy: A New Model of Treatment

Psychedelic-assisted psychotherapy is a developing model of treatment that combines the effects of psychedelics and psychotherapy. In this model, patients take a psychedelic substance in a controlled setting, under the supervision of a trained therapist. The altered state of consciousness induced by the psychedelic is used as a therapeutic tool, providing patients with new perspectives on their challenges, traumas, or behavioral patterns.

Future Directions

While the results of current research are promising, we are still in the early stages of understanding how best to use these substances in a therapeutic context. More large-scale, long-term studies are needed to ascertain the safety, efficacy, and optimal use of psychedelics in treating various mental health conditions. Researchers are also exploring other psychedelic substances, such as Ayahuasca and Ibogaine, for their potential therapeutic uses.


Psychedelics, once cast aside by the scientific community, are now on the brink of a renaissance in mental health treatment. Their potential to revolutionize therapy for treatment-resistant conditions offers hope to countless individuals. As research continues to evolve, it is our responsibility as clinicians, researchers, and informed public to approach this field with an open mind, backed by rigorous scientific inquiry, for the betterment of mental health care.

Psychedelics and Mental Health

Reach out today for a free consultation with a therapist in Boulder, CO.

  1. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.

  2. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71-78.

  3. Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513.

  4. Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019). MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9), 2735-2745.

  5. Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55-60.

  6. Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as medicines: an emerging new paradigm. Clinical Pharmacology & Therapeutics, 101(2), 209-219.

9 views0 comments


bottom of page